Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.

@article{Esser2002PreventionOE,
  title={Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.},
  author={Joost W J van Esser and Hubert G. M. Niesters and Bronno van der Holt and Ellen Meijer and Albert D M E Osterhaus and Jan Willem C. Gratama and Leo F. Verdonck and Bob L{\"o}wenberg and Jan B. W. J. Cornelissen},
  journal={Blood},
  year={2002},
  volume={99 12},
  pages={4364-9}
}
Recipients of a partially T-cell-depleted (TCD) allogeneic stem cell transplantation (allo-SCT) developing reactivation of Epstein-Barr virus (EBV) with quantified viral DNA levels exceeding 1000 genome equivalents/milliliter (geq/mL) are at high risk for EBV-lymphoproliferative disease (EBV-LPD). We studied whether preemptive therapy with rituximab prevents EBV-LPD, LPD-mortality, and abrogates viral reactivation in high-risk patients. We monitored 49 recipients of a TCD allo-SCT weekly for… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 123 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 36 references

Cytomegalovirus after BMT

  • MJ Boeckh, P. Ljungman
  • eds. Transplant Infections
  • 1998
Highly Influential
10 Excerpts

is essential for early detection of post - transplant lymphoproliferative disease in high - risk patients

  • KG Lucas, RL Burton, SE Zimmerman
  • 2001

Development of a real-time quantitative assay for detection of Epstein-Barr virus

  • HGM Niesters, J Van Esser, E Fries
  • J Clin Microbiol
  • 2000

Similar Papers

Loading similar papers…